The function of LncRNA-H19 in cardiac hypertrophy

Abstract

Cardiac hypertrophy, characterized by the enlargement of cardiomyocytes, is initially an adaptive response to physiological and pathological stimuli. Decompensated cardiac hypertrophy is related to fibrosis, inflammatory cytokine, maladaptive remodeling, and heart failure. Although pathological myocardial hypertrophy is the main cause of hypertrophy-related morbidity and mortality, our understanding of its mechanism is still poor. Long noncoding RNAs (lncRNAs) are noncoding RNAs that regulate various physiological and pathological processes through multiple molecular mechanisms. Recently, accumulating evidence has indicated that lncRNA-H19 is a potent regulator of the progression of cardiac hypertrophy. For the first time, this review summarizes the current studies about the role of lncRNA-H19 in cardiac hypertrophy, including its pathophysiological processes and underlying pathological mechanism, including calcium regulation, fibrosis, apoptosis, angiogenesis, inflammation, and methylation. The context within which lncRNA-H19 might be developed as a target for cardiac hypertrophy treatment is then discussed to gain better insight into the possible biological functions of lncRNA-H19 in cardiac hypertrophy.

Crosstalk of NLRP3 inflammasome and noncoding RNAs in cardiomyopathies

“…90 One example of a significant regulator of cardiac hypertrophy progression is the lncRNA-H19, as identified in previous studies. 91 In addition, lncRNAs have the ability to engage in interactions with miRNAs to modulate the expression of genes. This phenomenon can be facilitated through many ways, one of which involves functioning as miRNA sponges.…”

Phloretin alleviates palmitic acid-induced oxidative stress in HUVEC cells by suppressing the expression of LncBAG6-AS

“…For instance, LncH19, which is a conservative concern in cardiovascular or cancer research, can both act as a molecular sponge for miRNAs adsorption and interact with various proteins to regulate gene expression. 53,54 In exploring the mechanism of interest LncBAG6-AS action in this study, the most prevalent mechanism of the competitive adsorption of miRNAs was considered. However, due to the limitations of the long known fragment length and the inability to obtain the complete sequence of LncBAG6-AS by race, we preliminarily predicted several miRNAs binding to LncBAG6-AS through the online database, but the quantitative verification denied this hypothesis.…”

The Prospective Application of Melatonin in Treating Epigenetic Dysfunctional Diseases

“…LncRNA H19 has recently been implicated in the promotion of cardiomyocytes senescence by regulating the aging markers p53 and p21 ( Zhuang et al, 2021 ). The lncRNA H19 silenced the MALAT1 and MIAT in fibrosis-related cardiac hypertrophy resulting in increasing in senescence protein markers p53 and p21 ( Su et al, 2021 ). Melatonin on the hand actively produced antifibrotic action in cardiac fibrosis through inhibition of MALAT1 ( Che et al, 2020 ).…”